IQV

Healthcare

IQVIA

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2011–2025(15yr)

Revenue

Net Income

Free CF

Metric	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$4.3B	$4.9B	$5.1B	$5.5B	$5.7B	$6.9B	$9.7B	$10.4B	$11.1B	$11.4B	$13.9B	$14.4B	$15.0B	$15.4B	$16.3B	+5.9%
Gross Profit	$2.2B	$2.4B	$2.6B	$2.8B	$3.0B	$3.6B	$3.4B	$3.7B	$3.8B	$3.9B	$4.6B	$5.0B	$5.2B	$5.4B	$5.4B	+1.0%
Gross Margin	50.3%	49.5%	51.5%	50.8%	52.5%	53.0%	35.3%	35.2%	34.2%	34.0%	33.5%	34.9%	35.0%	34.9%	33.3%	-1.6pp
Operating Income	$345.3M	$396.4M	$462.3M	$590.4M	$646.6M	$642.0M	$719.0M	$741.0M	$777.0M	$731.0M	$1.4B	$1.8B	$2.0B	$2.2B	$2.2B	-0.9%
Operating Margin	8.0%	8.1%	9.1%	10.8%	11.3%	9.3%	7.4%	7.1%	7.0%	6.4%	10.0%	12.5%	13.2%	14.3%	13.4%	-0.9pp
Net Income	$241.8M	$177.5M	$226.6M	$356.4M	$387.2M	$115.0M	$1.3B	$259.0M	$191.0M	$279.0M	$966.0M	$1.1B	$1.4B	$1.4B	$1.4B	-0.9%
Net Margin	5.6%	3.6%	4.4%	6.5%	6.7%	1.7%	13.4%	2.5%	1.7%	2.5%	7.0%	7.6%	9.1%	8.9%	8.3%	-0.6pp
Free Cash Flow	—	—	—	—	—	$696.0M	$601.0M	$795.0M	$835.0M	$1.3B	$2.3B	$1.6B	$1.5B	$2.1B	$2.1B	-3.0%
FCF Margin	—	—	—	—	—	10.1%	6.2%	7.6%	7.5%	11.8%	16.6%	11.0%	10.0%	13.7%	12.6%	-1.1pp
EPS (Diluted)	$2.05	$1.51	$1.77	$2.72	$3.08	$0.76	$5.88	$1.24	$0.96	$1.43	$4.95	$5.72	$7.29	$7.49	$7.84	+4.7%

Total Debt$13.9B

Cash & Equiv.$2.0B

Net Debt$11.9B

4 min read

1. THE BIG PICTURE

IQVIA is attempting to institutionalize "Healthcare-grade AI" by layering proprietary algorithms over a staggering 68-petabyte dataset that covers 90% of the world’s pharmaceutical sales. While it remains a dominant force in clinical trial management and commercial intelligence, its future depends on whether it can use this scale to offset the structural margin pressures facing its biopharmaceutical clients.

2. WHERE THE RISKS HIT HARDEST

The "IQVIA Connected Intelligence" platform, which management cites as its primary differentiator, is structurally threatened by contractual volatility in the Research & Development Solutions (R&DS) segment. While this segment grew 9.9% in the most recent quarter (8-K), the fact that most clients can terminate contracts with 30 to 90 days' notice means that IQVIA’s $2.3 billion quarterly R&DS revenue stream is less "locked-in" than its massive backlog suggests (10-K Item 1A).

Furthermore, the "Proprietary Data Assets" strength is actually a hybrid vulnerability. While IQVIA processes 120 billion records annually, it remains dependent on 150,000 third-party suppliers. If these suppliers restrict access or raise prices, the Commercial Solutions business—which is being reorganized in 2026 to drive efficiency—could see its operating results materially harmed (10-K Item 1A).

3. WHAT THE NUMBERS SAY TOGETHER

The financial data reveals a company performing better in the short term than its long-term averages suggest. While TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter revenue growth sits at 5.9%, the most recent quarter showed a significant acceleration to 10.3% (8-K). This divergence is driven by "near double digit" growth across all segments, particularly a 18.6% surge in Contract Sales & Medical Solutions. However, this high-growth segment is being folded into the new "Commercial Solutions" unit in 2026, a move that suggests management is prioritizing operational discipline over maintaining standalone reporting lines.

The supplemental signals indicate a cautious but not bearish sentiment. Short interest stands at 3.5% of the float, suggesting some skepticism regarding IQVIA's ability to manage its $13.1 billion net debt (Yahoo Finance). Despite this debt, IQVIA leads its peer group in Free Cash Flow (FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders) margin at 13.0% and buyback yield at 4.2% (XBRL). This creates a paradox: IQVIA is aggressively returning capital to shareholders while carrying a 6.4x net leverage ratio that limits its operational flexibility.

4. IS IT WORTH IT AT THIS PRICE?

IQVIA is currently attractively valued relative to its peers. At a 12.3x forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, IQVIA trades at a nearly 30% discount to the peer median of 17.5x. This discount is likely a "leverage penalty" applied by the market for its $13.1 billion debt load, which is significantly higher than peers like Quest Diagnostics ($5.2B) or Labcorp ($4.5B).

At this multiple, the market is pricing in approximately 4.1% long-term growth (CAPM analysis). This appears highly achievable given that IQVIA’s actual revenue growth is currently 10.3% and management is guiding for 2026 revenues up to $17.35 billion (8-K). If IQVIA can maintain its 13.0% FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin—the highest in its peer group—and continue its 4.2% buyback yield, the implied EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric growth of 8.3% should easily outpace the market's low expectations.

5. WHAT WOULD CHANGE THIS VIEW?

Constructive if the 2026 segment reorganization leads to a measurable expansion in operating margins beyond the current 13.3%, or if net leverage falls toward the peer median.
Cautious if the projected $80 million increase in interest expense for 2026 grows further due to failed refinancing, or if R&DS backlog conversion slows due to client funding constraints.

6. BOTTOM LINE

Structural Advantage: A global, privacy-protected data moat comprising 1.2 billion patient records and 68 petabytes of proprietary healthcare information.

Bottom Line: IQVIA is a high-performing cash machine trading at a deep discount due to its debt, offering a compelling entry point if it can navigate a rising interest rate environment.

Source: Synthesis · LLM Analysis

4 min read

1. Top 5 Material Risks

Contractual Volatility: Most Research & Development Solutions clients can terminate contracts with 30 to 90 days' notice. Terminations or delays—often caused by clinical trial failures, lack of client funding, or regulatory actions—prevent IQVIA from realizing the full value of its backlog and can lead to lower resource utilization rates.
Third-Party Data Dependency: The Commercial Solutions business relies on numerous third-party data suppliers. If these suppliers increase prices, restrict data usage, or fail to meet quality standards, IQVIA’s ability to provide services is materially impacted, harming operating results.
Indebtedness and Covenants: IQVIA carries substantial debt, including senior secured credit facilities and notes issued by its subsidiary, IQVIA Inc. These agreements contain restrictive covenants, including a quarterly maximum senior secured net leverage ratio and minimum interest coverage ratio, which limit the ability to finance operations or engage in business activities.
Performance and Liability Exposure: Failure to perform services in accordance with regulatory standards (such as FDA, EMA, or GCP requirements) can result in significant costs, including the need to repeat clinical trials at IQVIA's expense, civil or criminal penalties, and damage to reputation.
Technological Obsolescence: The rapid evolution of AI and machine learning may render existing services obsolete. If IQVIA fails to keep pace with technological change or if clients shift to lower-cost, AI-enabled internal solutions, demand for IQVIA’s offerings could decline.

2. Company-Specific Risks

Client Concentration and Consolidation: While no single client represented 10% or more of revenues in 2025, 2024, or 2023, the majority of revenue is derived from a number of large clients. Industry consolidation often leads to the rationalization of drug development pipelines, reducing the volume of services purchased.
Therapeutic Class Concentration: Conducting multiple clinical trials for different clients within the same therapeutic class creates a risk that new scientific information or regulatory judgments affecting that class could lead to the cancellation of multiple trials simultaneously.
Restructuring Risks: Ongoing efforts to optimize business processes, such as the 2026 restructuring of reportable segments from three to two, present risks of service disruption, loss of key personnel, and the potential failure to achieve projected cost savings.
Corporate Governance Provisions: Provisions in the certificate of incorporation and Delaware law, such as the board's ability to issue preferred stock without stockholder approval, make hostile acquisitions difficult and may prevent stockholders from replacing management.

3. Regulatory/Legal Risks

Data Privacy Compliance: IQVIA is subject to complex global privacy laws, including HIPAA (U.S.), GDPR (EU), PIPEDA (Canada), and PIPL (China). Failure to comply with these regulations or the potential invalidation of data transfer frameworks (like the EU-U.S. Data Privacy Framework) could result in regulatory sanctions, criminal prosecution, or the blocking of data usage.
Anti-Corruption Laws: Global operations expose IQVIA to the U.S. Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act. Allegations of improper payments by employees or agents could lead to severe criminal or civil sanctions, including debarment from U.S. government business.
Healthcare Reform: Legislation such as the Inflation Reduction Act (IRA) and executive orders regarding drug pricing can pressure pharmaceutical pricing, potentially causing clients to reduce R&DR&DResearch & Development — spending on creating new products or technologies spending or marketing expenditures, thereby lowering demand for IQVIA’s services.

4. Financial Impact Map

Contractual Volatility → Revenues → The loss or delay of large contracts directly reduces the realization of backlog into recognized revenue. Third-Party Data Dependency → Operating Results → Increased costs from data suppliers or loss of access directly impacts the profitability of the Commercial Solutions segment. Indebtedness and Covenants → Cash Position / Debt Obligations → A breach of financial covenants could trigger the acceleration of indebtedness, requiring immediate repayment and potentially forcing bankruptcy or liquidation. Performance and Liability Exposure → Operating Expenses / Net Income → Costs associated with repeating clinical trials or defending against personal injury/negligence claims directly reduce net income. Technological Obsolescence → Revenues / Margins → Failure to compete with AI-enabled alternatives leads to pricing pressure and reduced demand for existing service offerings.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
14A	Feb 2026	—
10-K	Feb 2026	Dec 2025
8-K	Feb 2026	—
10-Q	Oct 2025	Sep 2025